She discusses the profile of the drug, which is currently in a phase 3 study, and the data Bluejay had previously presented on it. Plus, her advice for other entrepreneurs who might be fielding bids.

She discusses the launch and financial guidance for next year, and highlights obesity and Huntington's programs.

Biotech veteran and Summit Chairman Bob Duggan and Summit's Chief Strategy and Business Officer Dave Gancarz discuss the filing, and discuss trying to stay out front and on top in this emerging new class of medicines.

She describes the HOPE-3 data, the regulatory filing, which has already been initiated in part, and what she believes this treatment means for DMD patients.

He discusses programs covering dry eye, ocular pain, AMD, geographic atrophy, and more. Plus, how he using Bausch + Lomb's expertise in the eye and investing in biotech technologies of the future.

He discusses regulatory feedback the company has received that might allow it to earn an accelerated approval in antitrypsin deficiency. Plus, filing for sickle cell later this year, and how he thinks about new targets.

Founder and CEO Marshall Fordyce talks about the data that supported the application and describes how atacicept’s novel mechanism holds the potential to transform the treatment of the autoimmune disease. He says the company is getting ready to launch, with a PDUFA date set for July.

He discusses the company's degrader programs, TYK2/JAK1, using myostatin for obesity, and a Kv7 epilepsy program that will have key data this year.

He discusses the company's accomplishments to date, and highlights learnings about the mechanism and important data in 2026 in the maintenance setting for UC and Crohn's later this year.

He describes the asset, which has an extended half life and is designed to only inhibit the active form of C1s, and contrasts it with other medicines on the market today. Plus, the rationale for in-licensing a bispecific fusion protein that targets BDCA2 and BAFF/APRIL.

He discusses the causes of the rapid bounce biotech has witnessed over the last handful of months, his take on 2026, including the IPO environment, private vs public companies, areas of interest, and more.

Co-Founder and CEO Daniel Getts walks us through the platform, which is delivered via LNPs. The lead programs target TROP2, HER2, and GPC3.

CEO James Field and CSO Angus Sinclair discuss the Nectin-4 bi-specific, which is meant to have increased selectivity and potency and will compete with ADCs that are already on the market. Plus, how they are using their ML/AI expertise to help Sanofi with new programs.

Founder and CEO Michelle Lee highlights the key distinction between Medra and other automated lab equipment, which is that Medra's platform is designed to sense and understand its environment and use that knowledge to make its own intelligent decisions.

He talks about Kymera's dosing methodology, and recaps the data from a degradation, biomarker, and clinical outcomes standpoint. Plus, next steps in STAT6, and thoughts on the platform in general and the field more broadly.

CEO Abe Ceesay describes Rapport's precision neuroscience approach of targeting the AMPA receptor specifically through TARPγ8, and explains why the company took the extra step of tracking an electrographic biomarker in its phase 2a study in addition to seizure frequency. Plus, next steps and additional indications.

Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next. Coverage brought to you by

Founder and CEO Hervé Affagard walks us through how this treatment works and highlights the ASH presentation and one year survival data the company has accrued. Plus, how compassionate use is going in the United States. Coverage brought to you by

The therapy has shown single agent efficacy in patients who are refractory to BTKs. Plus, an update on global studies of the BCR-ABL/KIT, olverembatinib, and highlighting Ascentage's EED inhibitor. Coverage brought to you by

He describes the science behind ITK, and goes over ASH data in r/r T-cell lymphoma, where the company is already enrolling a pivotal study. Plus, why the profile of ITK in oncology gives him confidence in its utility for autoimmune disease, and highlighting atopic dermatitis data that will be coming in January. Coverage brought to you by